Leveraging our know-how and R&D approach, we have developed a robust clinical and pre-clinical pipeline through a combination of internally discovered and in-licensed products.
- Internal Discovery
- Business Development
- Translational Research
LAE001 exhibits favorable efficacy profile
for prostate cancer
Profound understanding
into fundamental
disease biology and clinical practice
Highly integrated global operation
that well-positions us to capture international business opportunities
Seasoned and top-tier management team
Drug Candidate
Target Mechanism
Indications
Lead
Discovery
Proof of
Mechanism
CMC IND Enabling
Phase I
Phase II
Commercial Rights
Licensor╱Partner
Cancer
Liver Fibrosis
Rare Disease
Glossary & abbreviations
PROC: platinum-resistant ovarian cancer mCPRC: metastatic castration-resistant prostate cancer mHSPC: metastatic hormone-sensitive prostate cancer ER: estrogen receptor TNBC: triple negative breast cancer HHT: hereditary hemorrhagic telangiectasia
As of March 13, 2023
AKT + Chemotherapy
PROC (second- to sixth-line treatment)
Global
AKT + CYP17A
mCRPC following SOC Treatment (second- to fourth-line treatment)
Global
AKT + PD-1+Chemotherapy
PD-1/PD-LI Resistant Solid Tumors
Global
AKT + PD-L1+chemotherapy
TNBC (second- to third-line treatment)
Global
AKT + ER
Locally Advanced or Metastatic HR+/HER2-Breast Cancer (second- to third-line treatment)
Global
CYP17A/CYP11B2
mHSPC (first-line treatment)
Global
ActRIIA
Cancer
Global
NK/T regulator
Cancer
Global
NK/Ø regulator
Cancer
Global
NK/T regulator
Cancer
Global
NK/T regulator
Cancer
Global
TAA
Cancer
Global
Low molecularweight compounds
Cancer
Global
Low molecularweight compounds
Cancer
Global
aHSC depletion
Liver Fibrosis
Global
aHSC depletion
Liver Fibrosis
Global
Conditional TGFß blocker
Liver Fibrosis
Global
AKT
HHT/Proteus Syndrome
Global
Glossary & abbreviations
PROC: platinum-resistant ovarian cancer mCRPC: metastatic castration-resistant prostate cancer mBC: metastatic breast cancer TNBC: triple negative breast cancer HHT: hereditary hemorrhagic telangiectasia ET: endocrine therapy AI: aromatase inhibitors
As of May 31, 2022
Conditions | Interventions | Study Title | Status |
---|---|---|---|
Solid Tumor TNBC Triple-Negative Breast Cancer |
Combination Product |
PhI to Solid Tumors and PhII to Locally Advanced or mTNBC |
Recruiting |
Platinum-resistant Ovarian Cancer |
Drug: Paclitaxel Drug: Afuresertib |
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian |
Recruiting |
Solid Tumor NSCLC Cervical Cancer Endometrial Cancer Esophageal CancerGastric and Gastroesophageal Junction Adenocarcinoma |
Drug: Afuresertib Drug:Nab paclitaxel Drug: Docetaxel Drug: Sintilimab |
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 |
Recruiting |
Metastatic Castration-resistant Prostate Cancer |
Drug: Phase I and Phase II: LAE001/prednisone + afuresertib |
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC |
Active,not recruiting |
Breast Cancer |
Drug: Afuresertib |
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer |
Recruiting |
In the 1990s, due to his passion for biotechnology, Dr. Xiangju Gu left his homeland to study and work overseas. Later, in order to realize hist dream of developing new drugs in China, he followed his heart and devoted to the wave of pharma innovation in Zhangjiang.
Follow us on Linkedin